HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DSHEA Legislative Reform Effort Likely In 108th Congress Behind Sen. Durbin

This article was originally published in The Tan Sheet

Executive Summary

Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff

You may also be interested in...

Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told

In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA

Supplements Containing Stimulants Would Need Preapproval Under Durbin Bill

Sen. Charles Schumer (D-N.Y.) is expected to co-sponsor the "Dietary Supplement Safety Act" (S 722), which was introduced March 26 by Sen. Richard Durbin (D-Ill.)

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts